Who are CapeOX（Capecitabine+Oxaliplatin）'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CVP, CEV chemotherapy, PTH followed by dose dense AC of FEC, SOX Chemotherapy, Dexamethasona, Idarubicine, ARA-C, Methotrexate, FEC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/capeox-capecitabine-oxaliplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

CapeOX（Capecitabine+Oxaliplatin） — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CapeOX（Capecitabine+Oxaliplatin） (CapeOX（Capecitabine+Oxaliplatin）) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy regimen. Area: Oncology.

phase 3 Combination chemotherapy regimen Thymidylate synthase (capecitabine); DNA (oxaliplatin) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CapeOX（Capecitabine+Oxaliplatin） (CapeOX（Capecitabine+Oxaliplatin）) — Peking University Cancer Hospital & Institute. CapeOX combines capecitabine, a fluoropyrimidine prodrug that inhibits thymidylate synthase, with oxaliplatin, a platinum agent that forms DNA crosslinks, to provide synergistic cytotoxic activity against cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CapeOX（Capecitabine+Oxaliplatin） TARGET	CapeOX（Capecitabine+Oxaliplatin）	Peking University Cancer Hospital & Institute	phase 3	Combination chemotherapy regimen	Thymidylate synthase (capecitabine); DNA (oxaliplatin)
CVP	CVP	SCRI Development Innovations, LLC	marketed	Combination chemotherapy regimen
CEV chemotherapy	CEV chemotherapy	Sun Yat-sen University	marketed	Combination chemotherapy regimen
PTH followed by dose dense AC of FEC	PTH followed by dose dense AC of FEC	Agendia	marketed	Combination chemotherapy regimen with monoclonal antibody	HER2 receptor; microtubule; DNA (topoisomerase II)
SOX Chemotherapy	SOX Chemotherapy	The First Affiliated Hospital with Nanjing Medical University	marketed	Combination chemotherapy regimen
Dexamethasona, Idarubicine, ARA-C, Methotrexate	Dexamethasona, Idarubicine, ARA-C, Methotrexate	PETHEMA Foundation	marketed	Combination chemotherapy regimen
FEC	FEC	Hoffmann-La Roche	marketed	Combination chemotherapy regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy regimen class)

Sun Yat-sen University · 5 drugs in this class
Sixth Affiliated Hospital, Sun Yat-sen University · 2 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
University Hospital, Bordeaux · 2 drugs in this class
Beijing Friendship Hospital · 1 drug in this class
Centre Hospitalier Universitaire Dijon · 1 drug in this class
Amgen · 1 drug in this class
Chungnam National University Hospital · 1 drug in this class
AstraZeneca · 1 drug in this class
Children's Cancer Group, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CapeOX（Capecitabine+Oxaliplatin） — Competitive Intelligence Brief. https://druglandscape.com/ci/capeox-capecitabine-oxaliplatin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab